RU2000112873A - APPLICATION OF ANTAGONISTS OF THE TUMOR NECROSIS FACTOR FOR THE PRODUCTION OF MEDICINES FOR THE TREATMENT OF SEPTIC DISEASES - Google Patents

APPLICATION OF ANTAGONISTS OF THE TUMOR NECROSIS FACTOR FOR THE PRODUCTION OF MEDICINES FOR THE TREATMENT OF SEPTIC DISEASES

Info

Publication number
RU2000112873A
RU2000112873A RU2000112873/14A RU2000112873A RU2000112873A RU 2000112873 A RU2000112873 A RU 2000112873A RU 2000112873/14 A RU2000112873/14 A RU 2000112873/14A RU 2000112873 A RU2000112873 A RU 2000112873A RU 2000112873 A RU2000112873 A RU 2000112873A
Authority
RU
Russia
Prior art keywords
tumor necrosis
necrosis factor
treatment
interleukin
tnf
Prior art date
Application number
RU2000112873/14A
Other languages
Russian (ru)
Inventor
Хартмут КУППЕР
Мартин КАУЛЬ
Юрген АЙЗЕЛЬШТАЙН
Лотар ДАУМ
Йоахим КЕМПЕНИ
Original Assignee
Кноль Акциенгезелльшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кноль Акциенгезелльшафт filed Critical Кноль Акциенгезелльшафт
Publication of RU2000112873A publication Critical patent/RU2000112873A/en

Links

Claims (7)

1. Способ лечения лиц, страдающих от сепсия, путем введения антагониста фактора некроза опухоли, отличающийся тем, что введение осуществляют при повышающемся уровне интерлейкина-6 (IL-6) в сыворотке крови в интервале измерения по крайней мере в 30 мин.1. A method of treating persons suffering from sepsia by administering a tumor necrosis factor antagonist, characterized in that the administration is carried out with increasing levels of interleukin-6 (IL-6) in the blood serum in the measurement interval of at least 30 minutes 2. Способ по п. 1, отличающийся тем, что введение осуществляют при уровне интерлейкина-6 (IL-6) в сыворотке крови 500 пг/мл и выше. 2. The method according to p. 1, characterized in that the introduction is carried out at a level of interleukin-6 (IL-6) in the blood serum of 500 pg / ml and above. 3. Способ по п. 1, отличающийся тем, что интервал измерения составляет 4-10 ч. 3. The method according to p. 1, characterized in that the measurement interval is 4-10 hours 4. Способ по п. 1, отличающийся тем, что в качестве антагониста фактора опухолевого некроза TNF применяют фрагмент F(ab')2 моноклонального антитела против фактора опухолевого некроза (анти-ТNР-антитела).4. The method according to p. 1, characterized in that as an antagonist of the tumor necrosis factor factor TNF, a fragment F (ab ') 2 of a monoclonal antibody against tumor necrosis factor (anti-TNP antibody) is used. 5. Торговая упаковка, содержащая антагонист фактора опухолевого некроза TNF вместе с инструкциями по применению этого антагониста TNF при лечении септических заболеваний, которые характеризуются повышающимся уровнем интерлейкина 6 (IL-6) в сыворотке в интервале измерения по крайне мере в 30 мин. 5. A trade package containing a tumor necrosis factor TNF antagonist along with instructions for using this TNF antagonist in the treatment of septic diseases, which are characterized by increasing serum interleukin 6 (IL-6) in the measurement interval of at least 30 minutes. 6. Упаковка по п. 5, отличающаяся тем, что в качестве антагониста TNF применяют антитело против фактора TNF (анти-ТNР-антитело). 6. Packaging according to claim 5, characterized in that an anti-TNF factor antibody (anti-TNP antibody) is used as a TNF antagonist. 7. Способ определения пригодности болеющиго сепсисом пациента для лечения антагонистами фактора опухолевого некроза, включающий определение уровня интерлейкина 6 (IL-6) в сыворотке крови в момент времени t1, определение уровня интерлейкина 6 (IL-6) в сыворотке крови в момент времени t2, который имеет интервал к моменту времени t1 по крайней мере в 30 мин, и определение соотношения
Figure 00000001

в том случае, если V>1, осуществление лечения антагонистами TNF.7. A method for determining the suitability of a patient with sepsis for treatment of tumor necrosis factor antagonists, comprising determining the level of interleukin 6 (IL-6) in blood serum at time t 1 , determining the level of interleukin 6 (IL-6) in blood serum at time t 2 , which has an interval at time t 1 of at least 30 minutes, and determining the ratio
Figure 00000001

in case V> 1, the implementation of treatment with TNF antagonists.
RU2000112873/14A 1997-10-23 1998-10-15 APPLICATION OF ANTAGONISTS OF THE TUMOR NECROSIS FACTOR FOR THE PRODUCTION OF MEDICINES FOR THE TREATMENT OF SEPTIC DISEASES RU2000112873A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19746868.3 1997-10-23

Publications (1)

Publication Number Publication Date
RU2000112873A true RU2000112873A (en) 2002-05-20

Family

ID=

Similar Documents

Publication Publication Date Title
US6235281B1 (en) Use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6
US11406688B2 (en) Compositions and methods for the systemic treatment of arthritis
WO2002096461A1 (en) Use of anti-tnf antibodies as drugs in treating septic disorders of anemic patients
US20030161828A1 (en) Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
ES2102360T3 (en) PROTEIN OF THE CELL SURFACE ASSOCIATED WITH LYMPHOCYTES.
AU756167B2 (en) Application of TNF antagonists as medicaments for treating septic diseases
RU2000112873A (en) APPLICATION OF ANTAGONISTS OF THE TUMOR NECROSIS FACTOR FOR THE PRODUCTION OF MEDICINES FOR THE TREATMENT OF SEPTIC DISEASES
Takao et al. Age-Related Reciprocal Modulation of lnterleukin-1βand lnterleukin-1 Receptors in the Mouse Brain-Endocrine-Immune Axis
KR100414505B1 (en) Use of anti-TNF antibodies as a drug for the treatment of diseases with high serum levels of interleukin-6
RU2001108716A (en) METHOD FOR TREATING PERSONS SUFFERING FROM SEPSIS
AU5394001A (en) The use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6
AU1549599A (en) The use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of the interleukin-6
MXPA00003355A (en) Application of tnf antagonists as medicaments for treating septic diseases
AU2012244136A1 (en) Compositions and methods for the systemic treatment of arthritis